EDRALBRUTINIB
Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
Jiangsu HengRui Medicine Co., Ltd.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →